Published in Nature Medicine, a novel urine test called uRARE-seq developed by researchers at Stanford Medicine and the VA Palo Alto health care system detects 95% of localized bladder cancer cases with 90% specificity. By capturing cell-free RNA fragments, the noninvasive liquid biopsy approach accurately evaluates tumor gene activity, outperforming standard urine cytology and DNA tests.
Urine Test Detects Bladder Cancer Without Invasive Procedures
- What it is: A noninvasive urine test that reads RNA messages released by bladder tumors rather than looking for DNA mutations.
- Why it matters: It spots cancer cells accurately without requiring invasive procedures or prior sequencing of the patient’s actual tumor tissue.
- What it does: Beyond initial detection, it helps doctors track whether residual disease remains after treatment and predicts how patients will respond to immunotherapy or chemotherapy.
Development of uRARE-seq and Diagnostic Performance
Bladder cancer traditionally demands resource-intensive surveillance protocols, driving clinical demand for reliable noninvasive biomarkers. Urine serves as an optimal medium for liquid biopsy because it makes direct physical contact with bladder neoplasms. However, previous investigations into urine cell-free RNA (cfRNA) focused narrowly on isolated genes. To broaden this scope, investigators designed uRARE-seq—short for urine random priming and affinity capture of cell-free RNA fragments for enrichment analysis by sequencing—as detailed in research published in Nature Medicine on October 2, 2026.
The team constructed a tumor-naive detection model evaluated on 151 bladder cancer patients and 100 noncancer controls. Selecting 381 genes, the model achieved an area under the curve (AUC) of 0.97, yielding 95% sensitivity at 90% specificity. An independent validation cohort comprising 142 bladder cancer patients and 140 noncancer controls reproduced similar performance. uRARE-seq maintained high sensitivity across varied tumor grades and stages:
| Tumor Grade and Stage | Total Cases | uRARE-seq Detected | Detection Rate |
|---|---|---|---|
| Low-grade Ta | 36 | 31 | 86% |
| High-grade Ta | 40 | 38 | 95% |
| Carcinoma in situ | 13 | 13 | 100% |
| High-grade T1 | 34 | 34 | 100% |
| High-grade T2 | 28 | 28 | 100% |
Overcoming Field-Effect Limitations in Liquid Biopsy
Conventional urine tumor DNA analyses frequently encounter a biological hurdle known as the field effect. Normal lining cells inside the urinary bladder often accumulate bystander mutations that mimic genetic signatures found in malignant tumors. Standard DNA assays can mistake these benign alterations for cancer, requiring clinicians to sequence both the patient’s tumor and healthy tissue beforehand to filter out noise.
By contrast, uRARE-seq bypasses this limitation by evaluating RNA expression messages rather than static DNA mutations. Evaluated subsets demonstrated that uRARE-seq performance remained consistent regardless of whether field-effect mutations were present. In 93 paired samples, uRARE-seq identified 89 bladder cancer cases (95.7%), compared to just 32 cases (34.4%) flagged by standard urine cytology.
Urine cfRNA Tracks Disease Recurrence and Therapy Response
Serial testing of urine cfRNA also provides visibility into minimal residual disease following surgical resection and bacillus Calmette-Guérin (BCG) immunotherapy. Patients maintaining detectable cfRNA after treatment faced higher recurrence risk than those with molecular complete responses after either surgery or BCG.
Pretreatment transcriptional profiles additionally exposed biological clues regarding therapeutic susceptibility. Patients who later responded to therapy more frequently showed RNA signals from genes associated with T cells and immune signaling. Conversely, in those who did not respond to treatment, signs of rapid tumor cell division predominated.
uRARE-Seq Remains Investigational and Unavailable for Clinical Practice
While uRARE-seq represents a promising diagnostic advancement, it remains investigational and is not yet available as a standard diagnostic kit in clinical practice.
Commercial Translation and Future Outlook
Commercialization efforts are already underway alongside clinical validation. Some authors involved in the foundational research maintain financial interests in Resero Bio, a company formed to commercialize the technology, and hold associated patents for cell-free RNA urine analysis. While initial findings published in Nature Medicine establish high diagnostic accuracy, validation cohorts were non-randomized, leaving room for potential unmeasured treatment-selection confounding. Larger, prospective multicenter trials remain necessary to confirm clinical utility before widespread adoption across global healthcare systems.
References
- Liu, K.J., Shi, W.Y., Nesselbush, M.C., et al. (2026). Urine cell-free RNA for bladder cancer detection and treatment response prediction. Nature Medicine. DOI: 10.1038/s41591-026-04673-3.
- Stanford Medicine and VA Palo Alto Health Care System. (2026). Research findings on uRARE-seq liquid biopsy applications in urology.
- News-Medical. (2026). Simple urine test can accurately diagnose and track bladder cancer.
- UA.News. (2026). Urine test detected 95% of localized bladder cancer cases.
Disclaimer: This article is for informational purposes only and does not constitute formal medical advice, diagnosis, or treatment recommendations. Always consult a qualified physician regarding urological symptoms or cancer surveillance protocols.
